The present study showed that the first-line pembrolizumab and chemotherapy combination had superior PFS than pembrolizumab monotherapy in patients with advanced NSCLC and high PD-L1 expression (>50%). The gene discussed is CD274; the disease is non-small cell lung carcinoma.